Search or
𝛼SK
𝛼SKSign in with Google. Opens in new tab
bullish
ARWR: PALISADE Phase 3 Results Published in NEJM
On September 2, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced results from the Phase 3 PALISADE study of plozasiran in patients with...
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 8-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Daiichi Sankyo Placement - US$1.2bn Deal but Momentum Isn’t the Best, Last Deal Didn’t Do Well
- UK CPI Trend Extends Excess In July
- Korea's Dividend Narrative Is Back: Unpacking the DP's New Bill and Its Backstory
- MV Australia Equal Weight Index Rebalance Preview: Three Potential Deletions in September
- EA: Sticky Inflation Survives Euro’s Surge
Top Unpaywalled Insights
More »- India-China Economic Relations: Navigating Massive Imbalances and Strategic Dependencies
- Kyivstar (KYIV US): Structural Long – From Ukraine’s Resilience to Renewal; Uklon Embedded Value
- How to Own Lenovo at a Discount: BUY Legend Holdings Corp (3396 HK)
- Institutions Are Coming for Bitcoin — UTXO’s Loren Asmus Explains How
- Curator's Cut: Singapore Unlocks Value, India’s Jewellery Caution & Taiwan's Top ETF's Rebalance
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- ARWR: PALISADE Phase 3 Results Published in NEJM 10 Sep 2024
x